Ching-Wei Chang Selected Research

Ching-Wei Chang Research Topics

Disease

15	Neoplasms (Cancer) 01/2022 - 11/2005
5	Triple Negative Breast Neoplasms 01/2022 - 01/2019
4	Hepatocellular Carcinoma (Hepatoma) 03/2020 - 03/2011
4	Chemical and Drug Induced Liver Injury 08/2016 - 01/2009
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 01/2019
2	Disease Progression 01/2022 - 10/2019
2	Breast Neoplasms (Breast Cancer) 01/2022 - 01/2019
2	Diarrhea 05/2021 - 01/2018
2	Inflammation (Inflammations) 05/2021 - 06/2012
2	Colorectal Neoplasms (Colorectal Cancer) 01/2020 - 01/2018
2	Adenocarcinoma 01/2020 - 01/2018
2	Renal Insufficiency (Renal Failure) 08/2019 - 01/2011
2	Chronic Renal Insufficiency 08/2019 - 11/2012
2	Disease Susceptibility (Diathesis) 01/2013 - 01/2012
2	Polyps 11/2011 - 08/2010
1	Bites and Stings (Sting) 01/2022
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2022
1	Hematologic Neoplasms (Hematological Malignancy) 01/2022
1	Body Weight (Weight, Body) 05/2021
1	Mucositis 05/2021
1	Ovarian Neoplasms (Ovarian Cancer) 11/2020
1	Lymphatic Metastasis 03/2020
1	Hepatitis C 01/2020
1	Lung Neoplasms (Lung Cancer) 01/2019
1	Simpson-Golabi-Behmel syndrome 06/2015
1	Obesity 01/2015
1	Weight Gain 01/2015
1	Acquired Immunodeficiency Syndrome (AIDS) 03/2014
1	Gallstones (Gallstone) 04/2013
1	Cholelithiasis 04/2013
1	End Stage Liver Disease 11/2012
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 06/2012
1	Carcinoma (Carcinomatosis) 06/2012
1	Necrosis 06/2012
1	Fibrosis (Cirrhosis) 01/2011
1	Stomach Ulcer (Gastric Ulcer) 08/2010

Drug/Important Bio-Agent (IBA)

6	Pharmaceutical PreparationsIBA 08/2016 - 01/2009
5	Biomarkers (Surrogate Marker)IBA 01/2022 - 08/2012
5	DNA (Deoxyribonucleic Acid)IBA 10/2019 - 06/2012
4	atezolizumabIBA 11/2020 - 01/2019
3	Fluorouracil (Carac)FDA LinkGeneric 05/2021 - 01/2018
2	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2020
2	CytokinesIBA 05/2021 - 01/2018
2	RNA (Ribonucleic Acid)IBA 01/2021 - 10/2019
2	B7-H1 AntigenIBA 11/2020 - 01/2019
2	Leucovorin (Folinic Acid)FDA Link 01/2020 - 01/2018
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2020 - 01/2018
2	FructoseIBA 06/2015 - 01/2015
2	Zidovudine (Retrovir)FDA LinkGeneric 03/2014 - 03/2011
1	entrectinibIBA 01/2022
1	venetoclaxIBA 01/2022
1	Circulating Tumor DNAIBA 01/2022
1	Fulvestrant (Faslodex)FDA Link 01/2022
1	Tyrosine Kinase InhibitorsIBA 01/2022
1	Complement System Proteins (Complement)IBA 01/2022
1	InterferonsIBA 01/2022
1	Estrogen ReceptorsIBA 01/2022
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2022
1	ChemokinesIBA 01/2022
1	Interleukin-6 (Interleukin 6)IBA 05/2021
1	Plant Preparations (Preparation, Plant)IBA 05/2021
1	PlatinumIBA 11/2020
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2020
1	Bevacizumab (Avastin)FDA Link 11/2020
1	monomethyl auristatin EIBA 11/2020
1	Sorafenib (BAY 43-9006)FDA Link 03/2020
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2020
1	Antiviral Agents (Antivirals)IBA 01/2020
1	LigandsIBA 01/2019
1	130-nm albumin-bound paclitaxelIBA 01/2019
1	Cell-Free Nucleic AcidsIBA 01/2019
1	Monoclonal AntibodiesIBA 01/2019
1	Chemokine CXCL10IBA 01/2019
1	Proteins (Proteins, Gene)FDA Link 01/2018
1	Messenger RNA (mRNA)IBA 01/2018
1	Blood Glucose (Blood Sugar)IBA 06/2015
1	Glucose (Dextrose)FDA LinkGeneric 06/2015
1	NucleosidesIBA 03/2014
1	Reverse Transcriptase InhibitorsIBA 03/2014
1	Interleukin-18 (Interleukin 18)IBA 04/2013
1	CreatinineIBA 11/2012
1	BilirubinIBA 11/2012
1	brassIBA 06/2012
1	furanIBA 06/2012
1	PyrimidinesIBA 06/2012
1	PurinesIBA 06/2012
1	CarcinogensIBA 06/2012
1	XenobioticsIBA 01/2012
1	PlasticsIBA 08/2010

Therapy/Procedure

9	Therapeutics 01/2022 - 11/2005
4	Drug Therapy (Chemotherapy) 05/2021 - 01/2018
2	Folfox protocol 01/2020 - 01/2018
1	Immunotherapy 11/2020
1	Radiotherapy 03/2020
1	Fecal Microbiota Transplantation 01/2020
1	Contraindications 08/2019
1	Adjuvant Chemotherapy 01/2019
1	Precision Medicine 01/2012
1	Ligation 11/2011
1	Liver Transplantation 01/2011